SuperworthSpruce Biosciences SPRB
- Market cap
- $129.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Spruce Biosciences' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.1M | $2.9M | $2M+2% | $1.6M−26% | $602K−80% | $697K−76% | $0 | $0 | $0 | $0 | n/a | n/a | |
| R&D | $13.5M+54% | $11.1M+26% | $10.3M−12% | $8.1M−38% | $6.6M−51% | $21.5M+93% | $10.8M+5% | −$430K | $5M−24% | $4.1M−81% | $7.6M−30% | $12.2M |
| SG&A | $3.2M+17% | $3M−10% | $4.3M+25% | $3.6M+18% | $3.5M+7% | $3.3M+12% | $3.7M−15% | $3.1M−12% | $3.2M−7% | $7M+111% | $4.4M+21% | $4.3M+39% |
| −$13.7M+18% | −$11.2M−8% | −$12.6M−4% | −$10M−28% | −$9.4M−31% | −$24.1M+116% | −$14.5M+15% | −$2.7M−73% | −$8.2M−13% | −$11.1M−54% | −$12M−17% | −$16.5M+513% | |
| Interest expense | $119K+8% | $106K−18% | $97K−26% | $83K−35% | $71K−40% | $56K−47% | $36K−63% | $29K−65% | $19K−73% | $6K−89% | $674K+1772% | $1.1M+3683% |
| Net income | −$12.4M+8% | −$9.9M−11% | −$11.6M−9% | −$9.2M−28% | −$8.7M−30% | −$23.6M+137% | −$14M+21% | −$2.1M−78% | −$8.2M−5% | −$14.6M−38% | −$12.3M−13% | −$16.2M+685% |
| −$22.50−38% | −$18.00−49% | −$21.00−30% | −$16.73−30% | −$15.75−30% | −$42.59+137% | −$23.95+14% | −$3.50−79% | −$14.58−7% | −$11.34−73% | −$8.94−63% | −$6.68+91% | |
| 542.8K+73% | 543.5K+73% | 547.9K+29% | 548.8K+2% | 550.6K+1% | 553.2K+2% | 586.1K+7% | 591.1K+8% | 563.1K+2% | 1.3M+134% | 1.4M+134% | 2.4M+311% |
EPS, diluted: 6 periods, Q4 FY19 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY19 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Spruce Biosciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SPRBSpruce Biosciences | $129.8M | n/m | n/a | n/m | n/m | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| Peer median | $523.1M | 11.3× | 13.6× | 1.4× | +7% | 11.6% |
More on Spruce Biosciences
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .